421 related articles for article (PubMed ID: 25057039)
21. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
[TBL] [Abstract][Full Text] [Related]
22. Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore.
Howe HS; Thong BYH; Kong KO; Chng HH; Lian TY; Chia FL; Tay KSS; Lau TC; Law WG; Koh ET; Leung BP
Clin Exp Immunol; 2017 Sep; 189(3):298-303. PubMed ID: 28388832
[TBL] [Abstract][Full Text] [Related]
23. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.
Zhao LD; Li Y; Smith MF; Wang JS; Zhang W; Tang FL; Tian XP; Wang HY; Zhang FC; Ba DN; He W; Zhang X
Lupus; 2010 Nov; 19(13):1534-49. PubMed ID: 20974656
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity.
Nagai M; Hirayama K; Ebihara I; Shimohata H; Kobayashi M; Koyama A
Nephron Clin Pract; 2011; 118(4):c339-45. PubMed ID: 21293157
[TBL] [Abstract][Full Text] [Related]
25. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.
Boghdadi G; Elewa EA
Rheumatol Int; 2014 Sep; 34(9):1217-23. PubMed ID: 24748505
[TBL] [Abstract][Full Text] [Related]
26. B-cell activating factor and A proliferation-inducing ligand in relation to intima-media thickness as biomarkers of premature atherosclerosis in systemic lupus erythematosus patients.
Shater H; Fawzy M; Farid A; El-Amir A; Fouad S; Madbouly N
Am J Med Sci; 2022 Nov; 364(5):646-654. PubMed ID: 35580639
[TBL] [Abstract][Full Text] [Related]
27. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
28. High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma.
Li YJ; Li ZM; Xia ZJ; Li S; Xia Y; Huang HQ; Huang JJ; Yi PY; Jiang WQ
Ann Hematol; 2015 Jan; 94(1):79-88. PubMed ID: 25146008
[TBL] [Abstract][Full Text] [Related]
29. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
30. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study.
Eilertsen GØ; Van Ghelue M; Strand H; Nossent JC
Rheumatology (Oxford); 2011 Dec; 50(12):2197-205. PubMed ID: 21984763
[TBL] [Abstract][Full Text] [Related]
32. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
33. Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis.
Kobayashi N; Kobayashi I; Mori M; Sato S; Iwata N; Shigemura T; Agematsu K; Yokota S; Koike K
J Rheumatol; 2015 Dec; 42(12):2412-8. PubMed ID: 26472413
[TBL] [Abstract][Full Text] [Related]
34. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Stohl W
Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
[TBL] [Abstract][Full Text] [Related]
36. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies.
López De Padilla CM; McNallan KT; Crowson CS; Bilgic H; Bram RJ; Hein MS; Ytterberg SR; Amin S; Peterson EJ; Baechler EC; Reed AM
J Rheumatol; 2013 Mar; 40(3):294-302. PubMed ID: 23322463
[TBL] [Abstract][Full Text] [Related]
37. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
38. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
[TBL] [Abstract][Full Text] [Related]
39. Serum BAFF and APRIL levels in patients with PBC.
Migita K; Ilyassova B; Kovzel EF; Nersesov A; Abiru S; Maeda Y; Komori A; Ito M; Yano K; Yatsuhashi H; Shimoda S; Ishibashi H; Nakamura M
Clin Immunol; 2010 Feb; 134(2):217-25. PubMed ID: 19840904
[TBL] [Abstract][Full Text] [Related]
40. The rationale for BAFF inhibition in systemic lupus erythematosus.
Davidson A
Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
